M.I.TECH CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7,980 KRW | 0.00% |
|
+11.30% | +18.05% |
| Sales 2021 | 50.26B 36.54M | Sales 2022 * | 57.9B 42.09M | Capitalization | 258B 188M |
|---|---|---|---|---|---|
| Net income 2021 | 12B 8.72M | Net income 2022 * | 18B 13.09M | EV / Sales 2021 | 2.99 x |
| Net cash position 2021 | 19.83B 14.42M | Net cash position 2022 * | 35B 25.44M | EV / Sales 2022 * | 3.86 x |
| P/E ratio 2021 |
13.8
x | P/E ratio 2022 * |
13.1
x | Employees | - |
| Yield 2021 |
1.48% | Yield 2022 * |
1% | Free-Float | 36.83% |
More Fundamentals
* Assessed data
More news
| 1 week | +11.30% | ||
| Current month | -0.37% | ||
| 1 month | +18.22% | ||
| 3 months | +21.28% | ||
| 6 months | +11.45% | ||
| Current year | +18.05% |
1 week
7 410.00
8 770.00
1 month
6 620.008 770.00
Current year
5 640.008 770.00
1 year
5 640.0014 950.00
3 years
4 280.0015 770.00
5 years
1 850.0015 770.00
10 years
1 850.0015 770.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jin-hyung Park
CEO | Chief Executive Officer | 56 | - |
Young-Woo Park
DFI | Director of Finance/CFO | 55 | 19-02-28 |
Jae-Oh Kwak
SAM | Sales & Marketing | 50 | 16-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jin-hyung Park
CEO | Chief Executive Officer | 56 | - |
Ja-Hyeong Gu
BRD | Director/Board Member | 59 | 16-08-31 |
Young-Woo Park
DFI | Director of Finance/CFO | 55 | 19-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 7,980 | 0.00% | 1,548,480 |
| 24-04-24 | 7,980 | -1.36% | 1,211,722 |
| 24-04-23 | 8,090 | +3.06% | 2,027,019 |
| 24-04-22 | 7,850 | +9.94% | 16,247,830 |
| 24-04-19 | 7,140 | -0.42% | 220,589 |
End-of-day quote Korea S.E., April 24, 2024
More quotes
MITECH CO.,LTD. is a Korea-based company mainly engaged in the manufacturing and sale of stents. Stents include biliary, esophagus, pyloric, large intestine, duodenal stents, and stents for sample and study, among others. The Companyâs stents are sold under the brand names of CHOOSTENT and HANAROSTENT. In addition, the Company is engaged in the manufacture and sale of low frequency therapies, crushers and blood glucose meters. The Company distributes its products within the domestic market and to overseas markets.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
7,980
KRW
Average target price
9,600
KRW
Spread / Average Target
+20.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.05% | 188M | |
| +12.59% | 128B | |
| -9.32% | 10.51B | |
| -0.39% | 8.71B | |
| +13.56% | 7B | |
| +25.94% | 5.02B | |
| +6.93% | 3.39B | |
| -1.64% | 3.02B | |
| -11.96% | 2.07B | |
| -7.25% | 2.06B |
- Stock Market
- Equities
- A179290 Stock
